Affiliation:
1. Department of Neurology Hôpital Sainte‐Anne Paris France
2. Université Paris Descartes Sorbonne Paris Cité Paris France
3. NSERM U894 Paris France
4. DHU Neurovasc Paris France
5. Department of Cardiology INSERM UMR 915 Institut du Thorax Nantes France
6. Institut du Thorax Centre Hospitalier Universitaire de Nantes Nantes France
7. Department of Cardiology Cochin Hospital APHP Paris France
8. Epidemiology and Clinical Research Unit Georges Pompidou European Hospital APHP Paris France
9. INSERM CIC 1418 Paris France
Abstract
Background
We conducted a systematic review and meta‐analysis of randomized controlled trials (
RCT
s) comparing patent foramen ovale (
PFO
) closure, anticoagulation, and antiplatelet therapy to prevent stroke recurrence in patients with
PFO
‐associated cryptogenic stroke.
Methods and Results
We searched Medline, Cochrane Library, and EMBASE through March 2018. The primary outcome was stroke recurrence. Pooled incidences, hazard ratios, and risk ratios (
RR
s) were calculated in random‐effects meta‐analyses.
PFO
closure was associated with a lower risk of recurrent stroke compared with antithrombotic therapy (antiplatelet therapy or anticoagulation: 3560 patients from 6
RCT
s;
RR
=0.36, 95%
CI
: 0.17–0.79; I
2
=59%). The effect of
PFO
closure on stroke recurrence was larger in patients with atrial septal aneurysm or large shunt (
RR
=0.27, 95%
CI
, 0.11–0.70; I
2
=42%) compared with patients without these anatomical features (
RR
=0.80, 95%
CI
, 0.43–1.47; I
2
=12%). Major complications occurred in 2.40% (95%
CI
, 1.03–4.25; I
2
=77%) of procedures. New‐onset atrial fibrillation was more frequent in patients randomized to
PFO
closure versus antithrombotic therapy (
RR
=4.33, 95%
CI
, 2.37–7.89; I
2
=14%). One
RCT
compared
PFO
closure versus anticoagulation (353 patients; hazard ratio=0.14, 95%
CI
, 0.00–1.45) and 2
RCT
s compared
PFO
closure versus antiplatelet therapy (1137 patients; hazard ratio=0.18, 95%
CI
, 0.05–0.63; I
2
=12%). Three
RCT
s compared anticoagulation versus antiplatelet therapy, with none showing a significant difference.
Conclusions
PFO
closure is superior to antithrombotic therapy to prevent stroke recurrence after cryptogenic stroke. The annual absolute risk reduction of stroke was low, but it has to be tempered by a substantial time at risk (at least 5 years) in young and middle‐aged patients.
PFO
closure was associated with an increased risk of atrial fibrillation.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Cited by
127 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献